BackgroundMedication non-adherence is the major risk factor for rejection episodes. The aim of this study was to determine the risk factors associated with adherence to immunosuppressive regimen and its barriers among kidney transplant (KT) recipients.MethodsA cross-sectional study was performed in two outpatient post-transplant clinics in Mashhad, northeast of Iran. All patients who attended the clinics from August to October 2017 were included. Patients’s knowledge, adherence to immunosuppressive regimen, and quality of life were measured using the Kidney Transplant Understanding Tool, Basel Assessment of Adherence to Immunosuppressive Medications Scale (BAASIS), and SF-12V2 questionnaire, respectively. The barriers in adhering immunosuppressive regimen were investigated by Immunosuppressive Therapy Barriers Scale. Logistic regression was used to screen the significant risk factors of medication non-adherence.ResultsIn this study, 244 KT recipients were included with a mean age of 39.6±12.5 years. Based on the BAASIS score, 111 (45.5%) patients were adherent to immunosuppressive regimen. Female patients were more likely to be adherent (OR=0.48, p<0.01). The patients with higher level of quality of life were more likely to follow immunosuppressive medications (OR=1.078, p<0.05). The main barriers were as follows: concurrent use of many immunosuppressants, lack of knowledge about the usefulness of immunosuppressive medications, confusion in medication taking, and difficulty in remembering medication taking.ConclusionMore than half of the KT recipients were non-adherence to immunosuppressive regimen. These findings highlight the need for designing interventions in order to reduce or eliminate these barriers and consequently increase medication adherence among KT recipients.
Introduction: Fibroblast growth factor 21 (FGF21) is a metabolic regulator with multiple
beneficial effects on glucose and lipid homeostasis and insulin sensitivity.
Objectives: The aim of this study was to investigate the relation between the serum level of
FGF21 with and metabolic syndrome (MS) in kidney transplant recipients.
Patients and Methods: We performed a cross-sectional study on 86 stable renal transplant
recipients to detect possible relation between serum FGF21 level and MS during October 2014
and Mach 2015. Patients with past history of diabetes mellitus were excluded.
Results: There were 43 patients in each group with and without MS. Totally, they were 52
(60.5%) male and 34 (39.5%) female. The mean age of the MS group was significantly higher
than that of non-MS group. There was not significant difference between mean serum
creatinine level and glomerular filtration rate (GFR) between two groups (P > 0.05). The MS
patients had higher weight and body mass index (BMI) (P < 0.05). The prevalence of BMI
>25 kg/m2 in MS group was 25 (58.8%) versus non-MS group that only 10 (23.3%) had this
condition (P < 0.05). The mean of FGF21 level in MS and non-MS groups was 1.23 ± 0.67 ng/l
and 1.18 ± 0.71 ng/l, respectively (P > 0.05). There was not significant difference of serum
FGF21 level between MS and non-MS patients (P > 0.05).
Conclusion: While the elevated serum FGF21 level was found in subjects with insulin resistant
states, however, this study revealed that serum FGF21 levels were not significantly increased
in renal transplanted recipients with MS as compared with non-MS group.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.